Literature DB >> 24647486

Functional expression of TLR9 in esophageal cancer.

Yanli Zhang1, Qiuyan Wang1, Ailing Ma2, Yunhong Li1, Rui Li1, Yin Wang1.   

Abstract

The Toll-like receptor 9 (TLR9) plays a crucial role in both innate and adaptive immune responses against infection and danger signals. Stimulation of TLR9 has been linked to invasion in various cancer cells in vitro. The present study evaluated the expression of TLR9 in human esophageal cancer (EC) cells and normal and malignant esophageal squamous epithelium, and examined the association between TLR9 expression, clinicopathological variables, and EC patient outcome. We further characterized the direct effects of TLR9 agonist CpG oligonucleotides (CpG ODN) and inhibitor chloroquine (CQ), on the proliferation and invasion of EC cells in vitro. RT-PCR, western blot, flow cytometry and immunohistochemical analysis were used to determine the expression of TLR9 in EC cell line TE10, and 90 cases of esophageal squamous cell carcinoma, including 30 cases of adjacent esophageal epithelium. The TLR9 expression was compared with tumor size, location, grade, stage and proliferation. We found basal expression of TLR9 in TE10 cells. Esophageal carcinomas exhibited TLR9 expression that was positively associated with tumor size, location and TNM stage (P<0.05). CpG ODN significantly enhanced the invasion of TE10 cells, which could be abrogated by a TLR9 inhibitor CQ. CpG ODN led to activation of NF‑κB and enhanced expression of matrix metalloproteinase (MMP)-2, MMP-7 and cyclooxygenase-2 (COX-2) mRNA. Expression of TLR9 in EC suggests a role of TLR9 related to cell proliferation and differentiation. Our findings indicate that TLR9 may represent a novel therapeutic target in this disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24647486     DOI: 10.3892/or.2014.3095

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

1.  Toll-like receptor 9 expression in the natural history of Barrett mucosa.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Heikki Takala; Kalervo Metsikkö; Petri Lehenkari; Juha Saarnio; Tuomo Karttunen
Journal:  Virchows Arch       Date:  2015-04-03       Impact factor: 4.064

2.  High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.

Authors:  Joni Leppänen; Olli Helminen; Heikki Huhta; Joonas H Kauppila; Joel Isohookana; Kirsi-Maria Haapasaari; Petri Lehenkari; Juha Saarnio; Tuomo J Karttunen
Journal:  Virchows Arch       Date:  2017-02-12       Impact factor: 4.064

Review 3.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

4.  Cell Free DNA of Tumor Origin Induces a 'Metastatic' Expression Profile in HT-29 Cancer Cell Line.

Authors:  István Fűri; Alexandra Kalmár; Barnabás Wichmann; Sándor Spisák; Andrea Schöller; Barbara Barták; Zsolt Tulassay; Béla Molnár
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

5.  IFNAR1 is a predictor for overall survival in colorectal cancer and its mRNA expression correlated with IRF7 but not TLR9.

Authors:  Liang-Che Chang; Chung-Wei Fan; Wen-Ko Tseng; Hui-Ping Chein; Tsan-Yu Hsieh; Jim-Ray Chen; Cheng-Cheng Hwang; Chung-Ching Hua
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 6.  The tumor microenvironment in esophageal cancer.

Authors:  E W Lin; T A Karakasheva; P D Hicks; A J Bass; A K Rustgi
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

7.  Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.

Authors:  Ciska Verbaanderd; Hannelore Maes; Marco B Schaaf; Vikas P Sukhatme; Pan Pantziarka; Vidula Sukhatme; Patrizia Agostinis; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2017-11-23

Review 8.  Toll-Like Receptor 9 Agonists for Cancer Therapy.

Authors:  Davide Melisi; Melissa Frizziero; Anna Tamburrino; Marco Zanotto; Carmine Carbone; Geny Piro; Giampaolo Tortora
Journal:  Biomedicines       Date:  2014-08-04

9.  Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development.

Authors:  Fatma El Zahraa Mohamed; Rajiv Jalan; Shane Minogue; Fausto Andreola; Abeba Habtesion; Andrew Hall; Alison Winstanley; Steven Olde Damink; Massimo Malagó; Nathan Davies; Tu Vinh Luong; Amar Dhillon; Rajeshwar Mookerjee; Dipok Dhar; Rajai Munir Al-Jehani
Journal:  Dig Dis Sci       Date:  2021-05-03       Impact factor: 3.199

10.  The Expression of Toll-like Receptors in Normal Human and Murine Gastrointestinal Organs and the Effect of Microbiome and Cancer.

Authors:  Heikki Huhta; Olli Helminen; Joonas H Kauppila; Tuula Salo; Katja Porvari; Juha Saarnio; Petri P Lehenkari; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2016-07-01       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.